Currently Viewing:
American Society of Clinical Oncology Annual Meeting
Currently Reading
Persephone Trial: Cutting Trastuzumab Duration by Half Safer, Efficacious in HER2-Positive Breast Cancer
May 29, 2018
Despite USPSTF Recommendations, Lung Screening Rates Low Among Heavy Smokers
May 31, 2018
Nelarabine With Chemotherapy Boosted Outcomes in Pediatric and YA Patients With T-Cell Cancers
June 01, 2018
Dr Leonard B. Saltz on Deciding When a Patient Should Receive NGS Testing
June 02, 2018
Promising Early Phase Results With bb2121 CAR T Treatment in Relapsed Refractory Multiple Myeloma
June 02, 2018
Dr Peter Paul Yu Discusses the Impact of Health Information Technology in Oncology
June 02, 2018
Identifying Rational Immunotherapy Combinations for Glioblastoma: A Progress Report
June 02, 2018
Dr James Lin Chen Outlines Information Needs in Era of Precision Medicine
June 02, 2018
Ellen Miller Sonet Highlights Financial Burdens of Patients With Cancer
June 02, 2018
Utilization Management in Oncology: Current Strategies and a Path Forward
June 02, 2018
Immune Checkpoint Inhibitors Improve Outcomes in Mismatch Repair Deficient CRC, but Can Induce irAEs
June 02, 2018
ZUMA-1: Response to Axi-cel at Three Months Prognostic for Remission in B-cell Lymphoma
June 03, 2018
Cetuximab With Chemoradiation Worse Than Chemoradiation Alone in Older Patients With HNSCC
June 03, 2018
Dr Michael Thompson: The Role of Precision Medicine in the Community Setting
June 03, 2018
Dr Victoria Villaflor Outlines Challenges With Pursuing Precision Medicine
June 03, 2018
Clinical Trials: Sharing the Road With Real-World Evidence
June 04, 2018
Phase 3 TAILORx Results Confirm Chemotherapy Unnecessary in 70% of Women With Early-Stage Breast Cancer
June 04, 2018
KEYNOTE-042 Confirms First-Line Pembrolizumab Superior to Chemotherapy in PD-L1–Low Advanced NSCLC
June 04, 2018
Cemiplimab, in GOG 3016, Looks to Break New Ground for Immunotherapy in Cervical Cancer
June 04, 2018
Nearly Half of Patients With Metastatic CSCC Respond to Cemiplimab, on Fast Track at FDA
June 04, 2018
Opdivo Plus Chemo Boosts Progression-Free Survival 26% Over Chemo Alone in Late-Stage NSCLC
June 04, 2018
Managing Cancer-Related Pain in the Era of the Opioid Crisis
June 06, 2018
Discussing the Cost Burden of Cancer With Patients
June 06, 2018
Study Underscores Value of PROs in Improving Lung Cancer Survival
June 07, 2018

Dr Dennis P. Scanlon Explains Costs Associated With the Opioid Epidemic

Individuals, families, and local, state, and federal government all have incurred costs as a result of the opioid epidemic, explained Dennis P. Scanlon, PhD, professor, Health Policy and Administration, and director, Center for Health Care and Policy Research, Pennsylvania State University.


Individuals, families, and local, state, and federal government all have incurred costs as a result of the opioid epidemic, explained Dennis P. Scanlon, PhD, professor, Health Policy and Administration, and director, Center for Health Care and Policy Research, Pennsylvania State University.

Transcript

What have been the costs—not necessarily health related—that have arisen as a result of the opioid epidemic?

The opioid crisis, obviously you can’t go a day without seeing multiple news stories it seems on this issue, and it is a major issue, really a tragedy for the health of the US population. Of course, the obvious is premature death, mortality, the impact on families, and so forth and so on, but when you extend beyond that, I think you can look at the cost of the opioid crisis in a variety of different dimensions. You can look at first of all, who bears those costs, and there you can look at the individuals who are affected themselves and the family members of those individuals. You can look at state governments, local governments, as well as the federal government. So, we tend to look at cost in a variety of different buckets.

For example, if you’re a Medicaid recipient, and a Medicaid recipient has an overdose or needs treatment or therapy, often times Medicaid is incurring cost that it would not have had to occur had that overdose not happened if we were able to prevent the epidemic. Often times, individuals with addictions and with overdose get into the criminal justice system, and that involves not only sort of policing, but often times incarceration, and then judicial service cost as well. So, if you look at cost of states of having to deal with just the corrections or the judicial services associated with these cases-—whether it’s from an overdoes or addiction, or whether somebody’s supplying the drugs—there are significant expenditures there as well.

You can look at foster care costs—children who find themselves without a parent, a parent removed from the home, a parent who suffered from a premature death—and states or counties are overloaded in their foster care load as a result of this epidemic, so it really is pervasive. But, I would say criminal justice, education, special education in particular, children youth and services costs, like foster care. There certainly the medical care expenditure costs—Medicaid commercial insurers, Medicare. So it really is a pervasive epidemic, and again, individuals, families, and then local, state, and federal government all have incurred cost as a result of this epidemic.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up